Name

Chronos Therapeutics

Legal name

TheraCryf plc

Website

https://chronostherapeutics.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical-Stage Pharmaceuticals / Neuroscience Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Drug development
• Neuroscience therapeutics
• Behavioral brain disorders
• Glioblastoma treatment
• Pharmaceutical licensing

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharma Licensing and Partnership Deals: As a pre-revenue clinical stage company, TheraCryf generates value by developing proprietary drug candidates through preclinical and early clinical stages, then licensing or partnering with mid-size to large pharmaceutical companies for late-stage development and commercialisation. Revenue would come from upfront payments, milestone payments, and royalties from partnership agreements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Chronos Therapeutics (TheraCryf plc) is a clinical-stage drug development company that discovers and advances proprietary small-molecule therapeutic candidates for behavioral brain disorders and glioblastoma. Its current portfolio comprises three candidates — Ox-1 (orexin-1 receptor antagonist for substance use disorders and anxiety), DAT (dopamine transporter inhibitor for central fatigue and narcolepsy), and SFX-01 (for glioblastoma, co-developed with Erasmus Medical Centre Rotterdam). The company's commercial model is to out-license these candidates to mid-size and large pharmaceutical partners after proof of concept.

Product overview

TheraCryf is a clinical stage therapeutics company developing a portfolio of innovative drug candidates for behavioural brain disorders and oncology. The company's pipeline consists of three distinct therapeutic candidates: Ox-1 (an orexin-1 receptor antagonist for substance use disorders and anxiety), DAT (a dopamine transporter inhibitor for fatigue and narcolepsy), and SFX-01 (a glioblastoma treatment developed in collaboration with Erasmus Medical Centre). The strategy is to demonstrate proof of concept for these proprietary candidates and then partner with larger pharmaceutical organisations for late-stage clinical trials and commercialisation.

Differentiator

Problem solved

Functional benefit

Products and services

• Ox-1 A candidate-stage orexin-1 receptor antagonist small molecule developed for the treatment of substance use disorders (opioid and alcohol abuse, binge eating disorder) and anxiety. Designed with high target specificity and a formulation intended to reduce bingeing behavior without affecting normal eating and to overcome side effects seen in other orexin-1 blocker programs. Intended to be licensed or partnered to larger pharmaceutical companies for late-stage clinical development and commercialization.
• DAT (Dopamine Transporter Inhibitor) A candidate-stage atypical inhibitor of the brain dopamine transporter mechanism, developed for alleviating central fatigue and reducing the impact of the orphan condition narcolepsy. Aims to be partnered with larger pharmaceutical companies for late-stage development and commercialization.
• SFX-01 A therapeutic candidate for glioblastoma (stage 4 malignant glioma), with pre-clinical models showing positive data on tumor shrinkage and extended survival times. Being progressed under a fully grant-funded collaboration with Erasmus Medical Centre Rotterdam.

Quantifiable outcome

• Pre-clinical models show positive data for SFX-01 on tumour shrinkage and extended survival times in glioblastoma models
• +1 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Erasmus Medical Centre RotterdamcoreStrategic or Co-development PartnerTheraCryf is working in collaboration with Erasmus Medical Centre Rotterdam, NL on a fully grant funded programme to bring SFX-01 to patients with glioblastoma. This collaboration leverages the medical centre's research capabilities and infrastructure for advancing the glioblastoma programme through preclinical and clinical development.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Acadia Pharmaceuticals: Established CNS specialty pharmaceutical company with commercial products in Parkinson's psychosis and Rett syndrome. Comparable CNS therapeutics focus but at broader commercial scale and later stage than TheraCryf.
• Alkermes: Established CNS specialty pharma with approved treatments for schizophrenia, depression, and addiction. Comparable focus on CNS indications including substance use disorders, but operating at much broader commercial scale.

Direct peers

• Neumora Therapeutics: Clinical-stage biopharma developing precision medicines for brain diseases including substance use disorders and other neuropsychiatric conditions. Direct overlap with TheraCryf's behavioural brain disorder focus, particularly in substance use.
• Praxis Precision Medicines: Clinical-stage company developing CNS therapeutics for epilepsy, movement disorders, and other neurology indications. Comparable stage and CNS therapeutic focus, with similar reliance on partnership and capital markets for pipeline advancement.
• Axsome Therapeutics: Commercial-stage CNS therapeutics company with FDA-approved products in depression and migraine and a pipeline targeting behavioural and neurological disorders. Comparable in CNS focus and innovator pharmaceutical approach, though at a later commercial stage.
• Intra-Cellular Therapies: CNS-focused biopharma commercialising therapies for schizophrenia, bipolar, and other neuropsychiatric conditions. Comparable CNS specialty pharmaceutical focus with later-stage commercial maturity.
• Sage Therapeutics: Specialty CNS biopharma developing therapeutics for depression, epilepsy, and other brain disorders. Comparable innovator-pharma approach to CNS indications with a partnership/licensing heritage (e.g., zuranolone collaboration).
• COMPASS Pathways: Clinical-stage CNS therapeutics company developing psilocybin-based treatments for treatment-resistant depression and other behavioural brain disorders. Closely comparable in stage, therapeutic focus area (behavioural/psychiatric), and partnership-oriented business model.

Emerging players

• Cybin: Clinical-stage CNS therapeutics company developing psychedelic-based treatments for depression, anxiety, and substance use disorders. Partial overlap with TheraCryf's substance use and anxiety focus, with a different mechanistic approach.
• Atai Life Sciences: Clinical-stage biopharma developing psychedelic-based therapies for mental health disorders including addiction and anxiety. Comparable behavioural brain disorder focus and stage, with partial overlap in addiction treatment approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chronos-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chronos Therapeutics